{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:12:29Z","timestamp":1791497549186,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Due to improved treatment options, more SMA patients reach childbearing age. Currently, limited data on pregnant SMA patients is available, especially in relation to disease-modifying therapies (DMT). This case report helps to elucidate new approaches for future guidelines in the management of pregnancy and SMA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case Report<\/jats:title>\n                <jats:p>A 33-year-old wheelchair-bound patient with SMA type 3 (sitter) became pregnant following 36 months of Nusinersen treatment. The last dose was administered in the third gestational week. After pregnancy was confirmed, therapy was stopped immediately. A healthy child was born in the 34th gestational week by caesarean section. After a short nursing period, Nusinersen was restarted 6 weeks after the expected gestational date. At this time, the patient reported deteriorated motor functions, which stabilized at a lower level compared to pre-pregnancy in the 2-year follow-up, despite restarting Nusinersen treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>So far, only few cases of successful pregnancies of SMA patients on DMT have been reported. In natural history, the majority of patients experienced an increased deterioration of motor function while fetal outcome was not impaired. Our case shows that although Nusinersen treatment was applied in the third gestational week prior to proof of pregnancy, outcome was positive for mother and child. Future studies will have to determine whether ongoing treatment with Nusinersen during pregnancy should be recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-04005-3","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T07:10:31Z","timestamp":1735974631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Miriam","family":"Hiebeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie C.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"4005_CR1","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M et al. Diagnosis and management of spinal muscular atrophy: part 1 : recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. 2018;28:103\u201315."},{"issue":"3","key":"4005_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2017","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with SMA types 1c-4. Eur J Neurol. 2017;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"key":"4005_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JMO Hagen","year":"2007","unstructured":"Hagen JMO, Glanzman AM, Mcdermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"4005_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"issue":"5","key":"4005_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836\u201342.","journal-title":"Muscle Nerve"},{"key":"4005_CR6","unstructured":"K\u00f6lbel H, M\u00fcller-Felber W. Titel der Leitlinie: Spinale Muskelatrophie (SMA), Diagnostik und Therapie Entwicklungsstufe : S1. 2021;(022)."},{"key":"4005_CR7","doi-asserted-by":"publisher","unstructured":"Abati E, Corti S. Pregnancy outcomes in women with spinal muscular atrophy: A review. J Neurol Sci [Internet]. 2018;388(March):50\u201360. Available from: https:\/\/doi.org\/10.1016\/j.jns.2018.03.001","DOI":"10.1016\/j.jns.2018.03.001"},{"issue":"1","key":"4005_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/BF00839207","volume":"239","author":"S Rudnik-Sch\u00f6neborn","year":"1992","unstructured":"Rudnik-Sch\u00f6neborn S, Zerres K, Ignatius J, Rietschel M. Pregnancy and spinal muscular atrophy. J Neurol. 1992;239(1):26\u201330.","journal-title":"J Neurol"},{"key":"4005_CR9","doi-asserted-by":"crossref","unstructured":"Howarth L, Glanville T. Management of a pregnancy complicated by type III spinal muscular atrophy. BMJ Case Rep. 2011;1\u20133.","DOI":"10.1136\/bcr.10.2010.3402"},{"key":"4005_CR10","doi-asserted-by":"publisher","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K et al. Two-year efficacy and safety of Risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol [Internet]. 2023;270(5):2531\u201346. Available from: https:\/\/doi.org\/10.1007\/s00415-023-11560-1","DOI":"10.1007\/s00415-023-11560-1"},{"key":"4005_CR11","doi-asserted-by":"publisher","unstructured":"Chiriboga CA, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J et al. JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with Risdiplam. J Neurol [Internet]. 2024;271(8):4871\u201384. Available from: https:\/\/doi.org\/10.1007\/s00415-024-12318-z","DOI":"10.1007\/s00415-024-12318-z"},{"issue":"10","key":"4005_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in Type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"key":"4005_CR13","doi-asserted-by":"crossref","unstructured":"Finkel RS, Al-Muhaizea M, Farrar MA, Nelson L, Prufer A, Servais L et al. RAINBOWFISH: a study of Risdiplam in newborns with presymptomatic spinal muscular atrophy (SMA) (4281). Neurology. 2021;96(15_supplement):2021.","DOI":"10.1212\/WNL.96.15_supplement.4281"},{"key":"4005_CR14","doi-asserted-by":"publisher","unstructured":"Kirschner J, Bernert G, Butoianu N, De Waele L, Fattal-Valevski A, Haberlova J et al. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy. Eur J Paediatr Neurol [Internet]. 2024;51(June):73\u20138. Available from: https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.001","DOI":"10.1016\/j.ejpn.2024.06.001"},{"key":"4005_CR15","unstructured":"Biogen. ANHANG I ZUSAMMENFASSUNG DER MERKMALE DES. ARZNEIMITTELS Spinraza 12\u00a0mg Injektionsl\u00f6sung [Internet]. 2017. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170530137918\/anx_137918_de.pdf"},{"key":"4005_CR16","doi-asserted-by":"publisher","unstructured":"Sch\u00f6n M, Domingues S, de Carvalho M, Oliveira Santos M. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy. Neurol Sci [Internet]. 2023;44(5):1803\u20134. Available from: https:\/\/doi.org\/10.1007\/s10072-023-06618-x","DOI":"10.1007\/s10072-023-06618-x"},{"key":"4005_CR17","doi-asserted-by":"crossref","unstructured":"Stawicka E, Skar\u017cy\u0144ska U, Lipiec A, Mazanowska N, Stankiewicz J, Gos M et al. The first patient in Poland treated for SMA with Nusinersen during pregnancy. J Clin Med. 2024;13(23).","DOI":"10.3390\/jcm13237366"},{"key":"4005_CR18","unstructured":"Biogen. Fachinformation Spinraza TM 12\u00a0mg Injektionsl\u00f6sung. 2024."},{"key":"4005_CR19","doi-asserted-by":"publisher","unstructured":"MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST et al. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs [Internet]. 2022;36(2):181\u201390. Available from: https:\/\/doi.org\/10.1007\/s40263-022-00899-0","DOI":"10.1007\/s40263-022-00899-0"},{"key":"4005_CR20","unstructured":"Europe E. Product Information Risdiplam [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf"},{"issue":"3","key":"4005_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/01.PHM.0000046621.00871.30","volume":"82","author":"R Yim","year":"2003","unstructured":"Yim R, Kirschner K, Murphy E, Parson J, Winslow C. Successful pregnancy in a patient with spinal muscular atrophy and Severe Kyphoscoliosis. Am J Phys Med Rehabil. 2003;82(3):222\u20135.","journal-title":"Am J Phys Med Rehabil"},{"issue":"2","key":"4005_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0003-9993(94)90401-4","volume":"75","author":"GT Carter","year":"1994","unstructured":"Carter GT, William Bonekat H, Milio L. Successful pregnancies in the presence of spinal muscular atrophy: two case reports. Arch Phys Med Rehabil. 1994;75(2):229\u201331.","journal-title":"Arch Phys Med Rehabil"},{"key":"4005_CR23","doi-asserted-by":"publisher","unstructured":"Argov Z, de Visser M. What we do not know about pregnancy in hereditary neuromuscular disorders. Neuromuscul Disord [Internet]. 2009;19(10):675\u20139. Available from: https:\/\/doi.org\/10.1016\/j.nmd.2009.07.004","DOI":"10.1016\/j.nmd.2009.07.004"},{"key":"4005_CR24","doi-asserted-by":"publisher","unstructured":"Elsheikh BH, Zhang X, Swoboda KJ, Chelnick S, Reyna SP, Kolb SJ et al. Pregnancy and delivery in women with spinal muscular atrophy. Int J Neurosci [Internet]. 2017;127(11):953\u20137. Available from: https:\/\/doi.org\/10.1080\/00207454.2017.1281273","DOI":"10.1080\/00207454.2017.1281273"},{"key":"4005_CR25","unstructured":"EMA Spinraza Product Information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/spinraza-epar-public-assessment-report_en.pdf"},{"key":"4005_CR26","unstructured":"fda.gov. Spinraza (Injection) [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf"},{"key":"4005_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler, Miriam Greckl E, Stahl K, et al. Safety and Treatment effects of Nusinersen in Longstanding Adult 5q-SMA type 3 \u2013 A prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365.","journal-title":"J Neuromuscul Dis"},{"key":"4005_CR28","doi-asserted-by":"publisher","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-katz O, Osmanovic A, Petri S et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol [Internet]. 2020;19(4):317\u201325. Available from: https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","DOI":"10.1016\/S1474-4422(20)30037-5"},{"key":"4005_CR29","first-page":"1","volume":"0","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;0:1\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"4005_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JND-210644","volume":"8","author":"M Hiebeler","year":"2021","unstructured":"Hiebeler M, Abicht A, Reilich P, Walter MC. Effect of discontinuation of Nusinersen Treatment in Long-Standing SMA3. J Neuromuscul Dis. 2021;8(4):537\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"4005_CR31","doi-asserted-by":"publisher","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S et al. Long-term efficacy and safety of Nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg Heal - Eur [Internet]. 2024;39:100862. Available from: https:\/\/doi.org\/10.1016\/j.lanepe.2024.100862","DOI":"10.1016\/j.lanepe.2024.100862"},{"issue":"2","key":"4005_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0960-8966(01)00271-1","volume":"12","author":"S Rudnik-Sch\u00f6neborn","year":"2002","unstructured":"Rudnik-Sch\u00f6neborn S, Breuer C, Zerres K. Stable motor and lung function throughout pregnancy in a patient with infantile spinal muscular atrophy type II. Neuromuscul Disord. 2002;12(2):137\u201340.","journal-title":"Neuromuscul Disord"},{"key":"4005_CR33","doi-asserted-by":"publisher","unstructured":"Nunes Vicente B, Oliveira Santos M. Unexpected but successful non-instrumental vaginal delivery in a spinal muscular atrophy type II pregnant patient. Neurol Sci [Internet]. 2021;42(9):3901\u20132. Available from: https:\/\/doi.org\/10.1007\/s10072-021-05344-6","DOI":"10.1007\/s10072-021-05344-6"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-04005-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T19:01:31Z","timestamp":1736017291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-04005-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4005"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-04005-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient has consented to participate in the publishing of her case. Ethics approval was not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has given written informed consent to the publication of her case including personal and clinical details and possible images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Miriam Hiebeler received Speaker Honoraria from Biogen. Maggie C. Walter has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, Pharnext, PTC Therapeutics, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Avexis, Biogen, PTC Therapeutics, Ultragenyx, Santhera, Sarepta, and worked as an ad-hoc consultant for AskBio, Audentes Therapeutics, Avexis, Biogen Pharma GmbH, Fulcrum Therapeutics, GLG Consult, Guidepoint Global, Gruenenthal Pharma, Novartis, Pharnext, PTC Therapeutics, Roche. Simone Thiele has no conflicts to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}